ANKİLOZAN SPONDİLİT VE İNSAN LÖKOSİT ANTİJENİ-B27 POZİTİFLİĞİNDE SİSTEMİK İMMÜN-İNFLAMASYON İNDEKSİ VE PAN-İMMÜN-İNFLAMASYON DEĞERİNİN PROGNOSTİK ÖNEMİ
Year 2024,
Volume: 25 Issue: 3, 244 - 252, 30.09.2024
Adem Keskin
,
Taner Karakaya
,
Recai Aci
,
Ozlem Sezer
,
Samet Semiz
,
Ferhat Şirinyıldız
,
İpek Okutan
Abstract
Amaç: Ankilozan spondilit (AS) hem otoimmün hem de otoinflamatuar bir hastalık olarak tanımlanır. Kronik inflamatuar hastalıklarda tanı amaçlı yaygın olarak kullanılan insan lökosit antijeni B27 (HLA-B27), AS dahil aksiyel spondiloartritin temel laboratuvar parametresidir. Tam kan sayımı parametrelerinin formüle edilmesiyle elde edilen sistemik immün-inflamasyon indeksi (SII) ve pan-immün-inflamasyon değeri (PIV), sistemik inflamasyonu ve lokal immün yanıtı yansıtan ve hastalıklarda prognozu öngören umut verici biyobelirteçlerdir. Bu çalışmanın amacı, AS hastalarında HLA-B27 pozitifliğini öngörmede SII ve PIV biyobelirteçlerinin duyarlılığını ve özgüllüğünü araştırmaktır.
Gereç ve Yöntemler: Çalışmaya HLA-B27 testleri pozitif olan 68 hasta (AS grubu) ve HLA-B27 testleri negatif olan 102 hasta (kontrol grubu) dahil edildi.
Bulgular: AS grubunda lenfosit ve ortalama trombosit hacmi değerleri kontrol grubuna göre düşük bulunurken, diğer tam kan sayımı parametreleri, eritrosit sedimantasyon oranı (ESR) ve C-reaktif protein (CRP) daha yüksek bulundu. AS grubunun SII ve PIV değerleri CRP ve ESR düzeyleri ile pozitif korelasyon gösterirken, kontrol grubunda korelasyon göstermedi. HLA-B27 pozitifliğini öngörmede PIV için duyarlılık %83,80, özgüllük %84,30 bulunurken, SII için duyarlılık %83,80, özgüllük %86,30 bulundu.
Sonuç: Kolayca ve hızla erişilebilen biyobelirteçler SII ve PIV, AS hastalarında HLA-B27 pozitifliğini tahmin etmek için potansiyel olarak kullanılabilir.
References
- 1. Yang H, Chen Y, Xu W, Shao M, Deng J, Xu S, et al. Epigenetics of ankylosing spondylitis: Recent developments. Int J Rheum Dis. 2021 Apr;24(4):487-493.
- 2. Mauro D, Thomas R, Guggino G, Lories R, Brown MA, Ciccia F. Ankylosing spondylitis: an autoimmune or autoinflammatory disease? Nat Rev Rheumatol. 2021 Jul;17(7):387-404.
- 3. Liu L, Yuan Y, Zhang S, Xu J, Zou J. Osteoimmunological insights into the pathogenesis of ankylosing spondylitis. J Cell Physiol. 2021 Sep;236(9):6090-6100.
- 4. Waeckel L, Kennel A, Berger AE, Lambert C. Human leukocyte antigen-B27 typing by flow cytometry: Comparison of three CE-IVD methods. Cytometry B Clin Cytom. 2023 Nov;104(6):460-467.
- 5. Fahed H, Mauro D, Ciccia F, Ziade NR. What Does Human Leukocyte Antigen B27 Have to Do with Spondyloarthritis? Rheum Dis Clin North Am. 2020 May;46(2):225-239.
- 6. Deodhar A, Gill T, Magrey M. Human Leukocyte Antigen B27-Negative Axial Spondyloarthritis: What Do We Know? ACR Open Rheumatol. 2023 Jul;5(7):333-344.
- 7. Tutan D, Doğan AG. Pan-Immune-Inflammation Index as a Biomarker for Rheumatoid Arthritis Progression and Diagnosis. Cureus. 2023 Oct 6;15(10):e46609.
- 8. Wu B, Zhang C, Lin S, Zhang Y, Ding S, Song W. The relationship between the pan-immune-inflammation value and long-term prognoses in patients with hypertension: National Health and Nutrition Examination Study, 1999-2018. Front Cardiovasc Med. 2023 Mar 2;10:1099427.
- 9. Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, Liu L. Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer. Sci Rep. 2019 Mar 1;9(1):3284.
- 10. Huang P, Mai Y, Zhao J, Yi Y, Wen Y. Association of systemic immune-inflammation index and systemic inflammation response index with chronic kidney disease: observational study of 40,937 adults. Inflamm Res. 2024 Apr;73(4):655-667.
- 11. Li G, Yu J, Jiang S, Wu K, Xu Y, Lu X, et al. Systemic Immune-Inflammation Index Was Significantly Associated with All-Cause and Cardiovascular-Specific Mortalities in Patients Receiving Peritoneal Dialysis. J Inflamm Res. 2023 Aug 31;16:3871-3878.
- 12. Lin F, Zhang LP, Xie SY, Huang HY, Chen XY, Jiang TC, Guo L, Lin HX. Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer. Front Oncol. 2022 Apr 13;12:830138.
- 13. Braun J, Sieper J. Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis. RMD Open. 2023 Aug;9(3):e003102.
- 14. Garrido-Mesa J, Brown MA. T cell Repertoire Profiling and the Mechanism by which HLA-B27 Causes Ankylosing Spondylitis. Curr Rheumatol Rep. 2022 Dec;24(12):398-410.
- 15. Oral D, Erdal GG, Tekeş S, Yücel I, Em S. Prevalence of HLA B27 in Patients Diagnosed with Ankylosing Spondylitis (AS) in Diyarbakır, Southeastern Region of Turkey. Niger J Clin Pract. 2024 Jan 1;27(1):29-34. doi: 10.4103/njcp.njcp_258_23. Epub 2024 Feb 5. PMID: 38317032.
- 16. Cui R, Wang YL, Tao YL, Tong Q, Chen Z, Dai SM. Platelet to albumin ratio is an independent indicator for disease activity in ankylosing spondylitis. Clin Rheumatol. 2023 Feb;42(2):407-413.
- 17. Uzeli Şen U, Başaran PO. Pan-immune inflammation value as a biomarker in ankylosing spondilitis and associated with disease activity. Anatolian Curr Med J. 2024;6(1):48-54.
- 18. Konsta M, Sakellariou GT, Rusman T, Sfikakis PP, Iliopoulos A, van der Horst-Bruinsma IE. Long-term effect of TNF inhibitors on radiographic progression in ankylosing spondylitis is associated with time-averaged CRP levels. Joint Bone Spine. 2021 May;88(3):105111.
- 19. Yılmaz O, Tutoğlu A, Garip Y, Ozcan E, Bodur H. Health-related quality of life in Turkish patients with ankylosing spondylitis: impact of peripheral involvement on quality of life in terms of disease activity, functional status, severity of pain, and social and emotional functioning. Rheumatol Int. 2013 May;33(5):1159-63.
- 20. Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19-34.
- 21. Chen YH, Huang WN, Chen YM, Lai KL, Hsieh TY, Hung WT, Lin CT, Tseng CW, Tang KT, Chou YY, Wu YD, Huang CY, Hsieh CW, Chen YJ, Liao YW, Chen HH. The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis. Front Med (Lausanne). 2022 May 16;9:856654.
SYSTEMIC IMMUNE INFLAMMATION INDEX AND PAN-IMMUNE INFLAMMATION VALUE IN PREDICTING HUMAN LEUKOCYTE ANTIGEN-B27 POSITIVITY: A STUDY ON ANKYLOSING SPONDYLITIS PATIENTS
Year 2024,
Volume: 25 Issue: 3, 244 - 252, 30.09.2024
Adem Keskin
,
Taner Karakaya
,
Recai Aci
,
Ozlem Sezer
,
Samet Semiz
,
Ferhat Şirinyıldız
,
İpek Okutan
Abstract
Objective: Ankylosing spondylitis (AS) is defined as both an auto-immune and autoinflammatory illness. Human leukocyte antigen B27 (HLA-B27), which is extensively employed in the diagnosis of chronic inflammatory diseases, is the basic laboratory parameter of axial spondylarthritis including AS. Systemic immune-inflammation index (SII) and pan-immune-inflammation value (PIV), obtained by formulating complete blood count parameters, are promising biomarkers that reflect systemic inflammation and local immune response and predict prognosis in diseases. The aim of this study was to investigate the sensitivity and specificity of SII and PIV biomarkers in predicting HLA-B27 positivity in AS patients.
Materials and Methods: The research included 68 individuals with HLA-B27 tests (+) (AS group) and 102 patients with HLA-B27 tests (-) (control group).
Results: In the AS group, lymphocyte and mean platelet volume values were determined to be lower than in the control group, while other complete blood count parameters, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), were found to be higher. While the SII and PIV values of the AS group determined a positive relation with CRP and ESR levels, they did not show a correlation in the control group. While the sensitivity for PIV in predicting HLA-B27 positivity was found to be 83.80% and the specificity was found to be 84.30%, for SII the sensitivity was found to be 83.80% and the specificity was found to be 86.30%.
Conclusion: Easily and rapidly accessible biomarkers SII and PIV can potentially be used to predict HLA-B27 positivity in AS patients.
Ethical Statement
The ethics committee decision for the research was taken at the Samsun University Non-Interventional Clinical Ethics Committee meeting held on February 28, 2024. (Protocol code: GOKAEK 2024/5/5).
References
- 1. Yang H, Chen Y, Xu W, Shao M, Deng J, Xu S, et al. Epigenetics of ankylosing spondylitis: Recent developments. Int J Rheum Dis. 2021 Apr;24(4):487-493.
- 2. Mauro D, Thomas R, Guggino G, Lories R, Brown MA, Ciccia F. Ankylosing spondylitis: an autoimmune or autoinflammatory disease? Nat Rev Rheumatol. 2021 Jul;17(7):387-404.
- 3. Liu L, Yuan Y, Zhang S, Xu J, Zou J. Osteoimmunological insights into the pathogenesis of ankylosing spondylitis. J Cell Physiol. 2021 Sep;236(9):6090-6100.
- 4. Waeckel L, Kennel A, Berger AE, Lambert C. Human leukocyte antigen-B27 typing by flow cytometry: Comparison of three CE-IVD methods. Cytometry B Clin Cytom. 2023 Nov;104(6):460-467.
- 5. Fahed H, Mauro D, Ciccia F, Ziade NR. What Does Human Leukocyte Antigen B27 Have to Do with Spondyloarthritis? Rheum Dis Clin North Am. 2020 May;46(2):225-239.
- 6. Deodhar A, Gill T, Magrey M. Human Leukocyte Antigen B27-Negative Axial Spondyloarthritis: What Do We Know? ACR Open Rheumatol. 2023 Jul;5(7):333-344.
- 7. Tutan D, Doğan AG. Pan-Immune-Inflammation Index as a Biomarker for Rheumatoid Arthritis Progression and Diagnosis. Cureus. 2023 Oct 6;15(10):e46609.
- 8. Wu B, Zhang C, Lin S, Zhang Y, Ding S, Song W. The relationship between the pan-immune-inflammation value and long-term prognoses in patients with hypertension: National Health and Nutrition Examination Study, 1999-2018. Front Cardiovasc Med. 2023 Mar 2;10:1099427.
- 9. Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, Liu L. Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer. Sci Rep. 2019 Mar 1;9(1):3284.
- 10. Huang P, Mai Y, Zhao J, Yi Y, Wen Y. Association of systemic immune-inflammation index and systemic inflammation response index with chronic kidney disease: observational study of 40,937 adults. Inflamm Res. 2024 Apr;73(4):655-667.
- 11. Li G, Yu J, Jiang S, Wu K, Xu Y, Lu X, et al. Systemic Immune-Inflammation Index Was Significantly Associated with All-Cause and Cardiovascular-Specific Mortalities in Patients Receiving Peritoneal Dialysis. J Inflamm Res. 2023 Aug 31;16:3871-3878.
- 12. Lin F, Zhang LP, Xie SY, Huang HY, Chen XY, Jiang TC, Guo L, Lin HX. Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer. Front Oncol. 2022 Apr 13;12:830138.
- 13. Braun J, Sieper J. Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis. RMD Open. 2023 Aug;9(3):e003102.
- 14. Garrido-Mesa J, Brown MA. T cell Repertoire Profiling and the Mechanism by which HLA-B27 Causes Ankylosing Spondylitis. Curr Rheumatol Rep. 2022 Dec;24(12):398-410.
- 15. Oral D, Erdal GG, Tekeş S, Yücel I, Em S. Prevalence of HLA B27 in Patients Diagnosed with Ankylosing Spondylitis (AS) in Diyarbakır, Southeastern Region of Turkey. Niger J Clin Pract. 2024 Jan 1;27(1):29-34. doi: 10.4103/njcp.njcp_258_23. Epub 2024 Feb 5. PMID: 38317032.
- 16. Cui R, Wang YL, Tao YL, Tong Q, Chen Z, Dai SM. Platelet to albumin ratio is an independent indicator for disease activity in ankylosing spondylitis. Clin Rheumatol. 2023 Feb;42(2):407-413.
- 17. Uzeli Şen U, Başaran PO. Pan-immune inflammation value as a biomarker in ankylosing spondilitis and associated with disease activity. Anatolian Curr Med J. 2024;6(1):48-54.
- 18. Konsta M, Sakellariou GT, Rusman T, Sfikakis PP, Iliopoulos A, van der Horst-Bruinsma IE. Long-term effect of TNF inhibitors on radiographic progression in ankylosing spondylitis is associated with time-averaged CRP levels. Joint Bone Spine. 2021 May;88(3):105111.
- 19. Yılmaz O, Tutoğlu A, Garip Y, Ozcan E, Bodur H. Health-related quality of life in Turkish patients with ankylosing spondylitis: impact of peripheral involvement on quality of life in terms of disease activity, functional status, severity of pain, and social and emotional functioning. Rheumatol Int. 2013 May;33(5):1159-63.
- 20. Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19-34.
- 21. Chen YH, Huang WN, Chen YM, Lai KL, Hsieh TY, Hung WT, Lin CT, Tseng CW, Tang KT, Chou YY, Wu YD, Huang CY, Hsieh CW, Chen YJ, Liao YW, Chen HH. The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis. Front Med (Lausanne). 2022 May 16;9:856654.